<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2025-24-1-42-49</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-2167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Генотипическое разнообразие вируса гепатита С среди больных туберкулезом в Томской области</article-title><trans-title-group xml:lang="en"><trans-title>Genotypic Diversity of Hepatitis C Virus in Tuberculosis Patients in the Tomsk Region</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Свирин</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Svirin</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кирилл Андреевич Свирин – младший научный сотрудник</p><p>р. п. Кольцово</p><p>+7 (913) 107-60-67</p></bio><bio xml:lang="en"><p>Kirill A. Svirin</p><p>Koltsovo</p><p>+7 (960) 977-98-06</p></bio><email xlink:type="simple">svirin_ka@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-2215-9032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Половкова</surname><given-names>О. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Polovkova</surname><given-names>O. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Геннадьевна Половкова – врач</p><p>г. Томск</p><p>+7 (960) 977-98-06</p></bio><bio xml:lang="en"><p>Oksana G. Polovkova</p><p>Tomsk</p><p>+7 (960) 977-98-06</p></bio><email xlink:type="simple">o_iwanowa@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-1829-0142</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федорова</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedorova</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Сергеевна Федорова – врач</p><p>г. Томск</p><p>+7 (913) 770-73-20</p></bio><bio xml:lang="en"><p>Elena S. Fedorova</p><p>Tomsk</p><p>+7 (913) 770-73-20</p></bio><email xlink:type="simple">e26015056@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-1788-4571</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Камалов</surname><given-names>М. H.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamalov</surname><given-names>M. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Hиколаевич Камалов – врач</p><p>г. Томск</p><p>+7 (923) 409-10-00</p></bio><bio xml:lang="en"><p>Mikhail N. Kamalov</p><p>Tomsk</p><p>+7 (923) 409-10-00</p></bio><email xlink:type="simple">kamalovmn@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Железнова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheleznova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алина Сергеевна Железнова – стажер-исследователь</p><p>р. п. Кольцово</p><p>+7 (953) 878-14-66</p></bio><bio xml:lang="en"><p>Alina S. Zheleznova</p><p>Koltsovo</p><p>+7 (953) 878-14-66</p></bio><email xlink:type="simple">zheleznova_as@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7857-6822</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карташов</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kartashov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Михаил Юрьевич Карташов – старший научный сотрудник</p><p>р. п. Кольцово</p><p>+7 (923) 419-31-92</p></bio><bio xml:lang="en"><p>Mikhail Yu. Kartashov</p><p>Koltsovo</p><p>+7 (923) 419-31-92</p></bio><email xlink:type="simple">kartashov_myu@vector.nsc.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГУН ГНЦ ВБ «Вектор» Роспотребнадзора</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Center of Virology and Biotechnology VECTOR</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ОГАУЗ «Томский фтизиопульмонологический медицинский центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk Phthisiopulmonological Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ОГАУЗ «Томский фтизиопульмонологический медицинский центр»,</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk Phthisiopulmonological Medical Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>08</day><month>03</month><year>2025</year></pub-date><volume>24</volume><issue>1</issue><fpage>42</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Свирин К.А., Половкова О.Г., Федорова Е.С., Камалов М.H., Железнова А.С., Карташов М.Ю., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Свирин К.А., Половкова О.Г., Федорова Е.С., Камалов М.H., Железнова А.С., Карташов М.Ю.</copyright-holder><copyright-holder xml:lang="en">Svirin K.A., Polovkova O.G., Fedorova E.S., Kamalov M.N., Zheleznova A.S., Kartashov M.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/2167">https://www.epidemvac.ru/jour/article/view/2167</self-uri><abstract><p>Актуальность. Больные туберкулезом (ТБ) люди входят в группу повышенного риска заболеваемости парентеральными вирусными гепатитами, в том числе гепатитом С (ГС). Гепатит С у больных туберкулезом часто можно выявить только в результате лабораторных исследований. Некоторые из противотуберкулезных препаратов имеют выраженный гепатотоксический эффект, что может приводить к тяжелым поражениям печени, особенно при сочетанной инфекции ТБ и ВГС.Цель. Определение генотипического разнообразия и молекулярно-генетическая характеристика изолятов ВГС, выделенных от пациентов, инфицированных туберкулезом, в Томской области.Материалы и методы. Исследование проведено на 117 образцах сывороток/плазмы крови, полученных от пациентов, инфицированных туберкулезом. Выявленные изоляты ВГС генотипировали путем амплификации фрагмента гена core в двухраундовой ПЦР с последующим определением нуклеотидных последовательностей полученных ампликонов. Вирусную нагрузку определяли методом количественной ОТ-ПЦР.Результаты и обсуждение. Выявлено следующее распределение субтипов в изучаемой выборке: 1b (47,0%; 95% ДИ: 38,2–56,0), 3a (32,5%; 95% ДИ: 24,7–41,3), 1a (18,0%; 95% ДИ: 12,1–25,8) и рекомбинант 2k/1b (2,5%; 95% ДИ: 0,9–7,2). Среди вариантов субтипа 1b установлены полиморфизмы в гене core, ассоциированные с устойчивостью к лечению интерферонами: среди 35 изолятов обнаружена мутация L91M (63,6%; 95% ДИ: 50,4–75,0), у 19 изолятов − замены в позиции R70Q/H (34,6%; 95% ДИ: 23,4–47,7). Обе замены обнаружены у 11 изолятов (20,0%; 95% ДИ: 11,5–32,3). Различий в распределении субтипов между четырьмя возрастными группами (младше 36, 36–40, 41–45, старше 45) не обнаружено. Выявлены достоверные различия (χ² Пирсона = 9,38; р = 0,025) в распределении субтипов между обследованными мужчинами и женщинами. У мужчин преобладал субтип 1b, у женщин – субтип 3a, и практически не было инфицированных с субтипом 1a, в отличие от пациентов мужского пола.Заключение. Исследование ВГС среди инфицированных туберкулезом важно для выбора наиболее подходящей тактики лечения пациентов, профилактики осложнений микст-инфицирования, а также для планирования и реализации профилактических мероприятий.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. People with tuberculosis (TB) are at an increased risk of spreading parenteral viral hepatitis, including hepatitis C virus (HCV). Hepatitis C in tuberculosis patients can often be detected only as a result of laboratory tests. Some of the anti-tuberculosis drugs have a pronounced hepatotoxic effect, which can lead to severe liver damage, especially in cases of combined TB and HCV infection.Aim. Determination of genotypic diversity and molecular genetic characteristics of HCV isolates isolated from patients infected with tuberculosis in the Tomsk region.Materials and methods. The study was conducted on 117 blood serum/plasma samples obtained from patients infected with tuberculosis. The identified HCV isolates were genotyped by amplifying a fragment of the core gene in two-round PCR followed by determination of the nucleotide sequences of the resulting amplicons. Viral load was determined by quantitative RT-PCR.Results and discussion. The following distribution of subtypes in the studied sample was revealed: 1b (47.0%; 95% CI: 38.2–56.0), 3a (32.5%; 95% CI: 24.7–41.3), 1a (18.0%; 95% CI: 12.1–25.8) and recombinant 2k/1b (2.5%; 95% CI: 0.9–7.2). Among the variants of subtype 1b, polymorphisms in the core gene were identified, associated with resistance to interferon treatment: among 35 isolates, the L91M mutation was detected (63.6%; 95% CI: 31.4–56.7), substitutions at position R70Q were detected in 19 isolates /H (34.6%; 95% CI: 7.6–26.1). Both substitutions were found in 11 isolates (20.0%; 95% CI: 11.5–32.3). No differences were found in the distribution of subtypes between the four age groups (under 36, 36–40, 41–45, over 45). Significant differences were revealed (Pearson's χ² = 9.38; p = 0.025) in the distribution of subtypes between the examined men and women. In men, subtype 1b predominated, in women, subtype 3a predominated and there were practically no people infected with subtype 1a, unlike male patients.Conclusion. HCV research among tuberculosis-infected people is important for choosing the most appropriate treatment tactics for patients, preventing complications of co-infection, as well as for planning and implementing preventive measures.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>вирус гепатита С</kwd><kwd>гепатит С</kwd><kwd>туберкулез</kwd><kwd>микст-инфицирование</kwd><kwd>генотипирование Конфликт интересов не заявлен</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hepatitis C virus</kwd><kwd>hepatitis C</kwd><kwd>tuberculosis</kwd><kwd>mixinfection</kwd><kwd>genotyping</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ballester-Ferré M.P., Martínez F., Garcia-Gimeno N., et al. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World Journal of Hepatology. 2017. Vol. 9, N3. P. 161–166. doi: 10.4254/wjh.v9.i3.161</mixed-citation><mixed-citation xml:lang="en">Ballester-Ferré M.P., Martínez F., Garcia-Gimeno N., et al. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin. World Journal of Hepatology. 2017;9(3):161–166. doi: 10.4254/wjh.v9.i3.161</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tuberculosis in Russian Federation [Internet]. World Health Organization. Доступно на: https:. worldhealthorg.shinyapps.io/TBrief/?_inputs_&amp;entity_type=%22country%22&amp;iso2=%22RU%22&amp;sidebarCollapsed=true&amp;sidebarItemExpanded=null. Ссылка активна на 24 июня 2024.</mixed-citation><mixed-citation xml:lang="en">Tuberculosis in Russian Federation [Internet]. World Health Organization. Available at: https://worldhealthorg.shinyapps.io/TBrief/?_inputs_&amp;entity_type=%22country%22&amp;iso2=%22RU%22&amp;sidebarCollapsed=true&amp;sidebarItemExpanded=null. Accessed: 24 June 2024.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hepatitis C [Internet]. World Health Organization. Доступно на: https:. www.who.int/news-room/fact-sheets/detail/hepatitis-c. Ссылка активна на 24 июня 2024.</mixed-citation><mixed-citation xml:lang="en">Hepatitis C [Internet]. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed: 24 June 2024.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т., Чуланов В. П., Мамонова Н. А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Национального научного общества инфекционистов по диагностике и лечению хронического вирусного гепатита С. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023. Т. 33, № 1. С. 84–124. doi: 10.22416/1382-4376-2023-33-1-84-124.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V.T., Chulanov V.P., Mamonova N.A., et al. Klinicheskie rekomendatsii Rossiiskogo obshchestva po izucheniyu pecheni, Rossiiskoi gastroenterologicheskoi assotsiatsii, Natsionalnogo nauchnogo obshchestva infektsionistov po diagnostike i lecheniyu khronicheskogo virusnogo gepatita C. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii. 2023;33(1):84–124 (In Russ). doi: 10.22416/1382-4376-2023-33-1-84-124</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Соловьев Д. В. Эпидемиологические особенности вирусных гепатитов В и С у больных туберкулезом легких м и тактика их профилактики. Дис. канд. мед. наук. Москва; 2012.</mixed-citation><mixed-citation xml:lang="en">Solovev D.V. Epidemiologicheskie osobennosti virusnykh gepatitov B i C u bolnykh tuberkulezom legkikh m i taktika ikh profilaktiki [dissertation]. Moscow; 2012. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Асратян А. А., Соловьев Д. В., Русакова Е. В. Современная эпидемическая ситуация по заболеваемости вирусными гепатитами и туберкулезом в Москве. Эпидемиология и Вакцинопрофилактика. 2015. Т. 14, № 3. С. 42–48. doi: 10.31631/2073-3046-2015-14-3-42-48</mixed-citation><mixed-citation xml:lang="en">Asratyan A.A., Solovev D.V., Rusakova E.V. Sovremennaya epidemicheskaya situatsiya po zabolevaemosti virusnymi gepatitami i tuberkulezom v Moskve. Èpidemiologiâ i vakcinoprofilaktika. 2015;14(3):42–48 (In Russ). doi: 10.31631/2073-3046-2015-14-3-42-48</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Manca C., Tsenova L., Bergtold A., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proceedings of the National Academy of Science USA. 2001. Vol. 98, N 10. P. 5752–5757. doi: 10.1073/pnas.091096998</mixed-citation><mixed-citation xml:lang="en">Manca C., Tsenova L., Bergtold A., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proceedings of the National Academy of Science USA. 2001;98(10):5752–5757. doi: 10.1073/pnas.091096998</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kempker R.R., Alghamdi W.A., Al-Shaer M.H., et al. A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrobial Agents and Chemotherapt. 2019. Vol. 63, N12. P: e01215–e01219. doi: 10.1128/aac.01215-19</mixed-citation><mixed-citation xml:lang="en">Kempker R.R., Alghamdi W.A., Al-Shaer M.H., et al. A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrobial Agents and Chemotherapt. 2019;63(12):e01215–e01219. doi: 10.1128/aac.01215-19</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Olaru I.D., Beliz Meier M., Mirzayev F., et al. Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and metaanalysis. eClinicalMedicine. 2023. Vol. 58. P. 101938. doi: 10.1016/j.eclinm.2023.101938</mixed-citation><mixed-citation xml:lang="en">Olaru I.D., Beliz Meier M., Mirzayev F., et al. Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and metaanalysis. ClinicalMedicine. 2023;58:101938. doi: 10.1016/j.eclinm.2023.101938</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim W.S., Lee S.S., Lee C.M., et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infectious Diseases. 2016. Vol. 16. P. 50. doi: 10.1186/s12879-016-1344-2</mixed-citation><mixed-citation xml:lang="en">Kim W.S., Lee S.S., Lee C.M., et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infectious Diseases. 2016;16:50. doi: 10.1186/s12879-016-1344-2</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. 1998. Vol. 157, N6, Pt 1. P. 1871–1876. doi: 10.1164/ajrccm.157.6.9711039</mixed-citation><mixed-citation xml:lang="en">Ungo J.R., Jones D., Ashkin D., et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. 1998;157(6 Pt 1):1871–1876. doi: 10.1164/ajrccm.157.6.9711039</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lin S.Y., Chen T.C., Lu P.L., et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infectious Diseases. 2014. Vol.14, P. 705. doi: 10.1186/s12879-014-0705-y</mixed-citation><mixed-citation xml:lang="en">Lin S.Y., Chen T.C., Lu P.L., et al. Incidence rates of tuberculosis in chronic hepatitis C infected patients with or without interferon based therapy: a population-based cohort study in Taiwan. BMC Infectious Diseases. 2014;14:705. doi: 10.1186/s12879-014-0705-y</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zein N.N. Clinical significance of hepatitis C virus genotypes . Clinical Microbiology Reviews. 2000. Vol. 13, N2. P. 223–235. doi: 10.1128/CMR.13.2.223</mixed-citation><mixed-citation xml:lang="en">Zein N.N. Clinical significance of hepatitis C virus genotypes. Clinical Microbiology Reviews. 2000;13(2):223–235. doi: 10.1128/CMR.13.2.223</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Probst A., Dang T., Bochud M., et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. Journal of Viral Hepatitis. 2011. Vol. 18, N11. P. 745–759. doi: 10.1111/j.1365-2893.2011.01481.x</mixed-citation><mixed-citation xml:lang="en">Probst A., Dang T., Bochud M., et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. Journal of Viral Hepatitis. 2011;18(11):745–759. doi: 10.1111/j.1365-2893.2011.01481.x</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998. Vol. 352, N9138. P. 1426–1432. doi: 10.1016/s0140-6736(98)07124-4</mixed-citation><mixed-citation xml:lang="en">Poynard T., Marcellin P., Lee S.S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426–1432. doi: 10.1016/s0140- 6736(98)07124-4</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Средневзвешенная стоимость схемы лечения гепатита С составляет 300—400 тыс. рублей. Фармацевтический Вестник. Доступно на: https: pharmvestnik.ru/content/news/Srednevzveshennaya-stoimost-shemy-lecheniya-gepatita-S-sostavlyaet-300-400-tys-rublei.html. Ссылка активна на 24 июня 2024.</mixed-citation><mixed-citation xml:lang="en">Srednevzveshennaya stoimost skhemy lecheniya gepatita S sostavlyaet 300—400 tys. rublei [Internet]. Farmatsevticheskii Vestnik. Available at: https://pharmvestnik.ru/content/news/Srednevzveshennaya-stoimost-shemy-lecheniya-gepatita-S-sostavlyaet-300-400-tys-rublei.html. Accessed: 24 June 2024.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Акимов И. А., Тимофеев Д. И., Мавзютов А. Р. и др. Выявление циркулирующей рекомбинантной формы RF1_2k/1b вируса гепатита С в сыворотке крови пациентов методом ОТ-ПЦР в режиме реального времени. Клиническая лабораторная диагностика. 2021. Т. 66, №2. С. 122–128. doi: 10.51620/0869-2084-2021-66-122-128</mixed-citation><mixed-citation xml:lang="en">Akimov I.A., Timofeev D.I., Mavzyutov A.R., et al. Vyyavlenie tsirkuliruyushchei rekombinantnoi formy RF1_2k/1b virusa gepatita C v syvorotke krovi patsientov metodom OT-PСR v rezhime realnogo vremeni. Klinicheskaya laboratornaya diagnostika. 2021;66(2):122–128. (In Russ). doi: 10.51620/0869-2084-2021-66-122-128</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology. 2008. Vol. 48, N1. P. 148–162. doi: 10.1016/j.jhep.2007.07.033</mixed-citation><mixed-citation xml:lang="en">Esteban J.I., Sauleda S., Quer J. The changing epidemiology of hepatitis C virus infection in Europe. Journal of Hepatology. 2008;48(1):148–162. doi: 10.1016/j.jhep.2007.07.033</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pimenov N., Kostyushev D., Komarova S., et al. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens. 2022 Vol. 11, N12. P. 1482. doi: 10.3390/pathogens11121482</mixed-citation><mixed-citation xml:lang="en">Pimenov N., Kostyushev D., Komarova S., et al. Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia. Pathogens. 2022;11(12):1482. doi: 10.3390/pathogens11121482</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kichatova V.S., Kyuregyan K.K., Soboleva N.V., et al. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. Journal of Immunology Research. 2018. Vol. 2018. P. 7685371. doi: 10.1155/2018/7685371</mixed-citation><mixed-citation xml:lang="en">Kichatova V.S., Kyuregyan K.K., Soboleva N.V., et al. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. Journal of Immunology Research. 2018;2018:7685371. doi: 10.1155/2018/7685371</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chida T., Watanabe S., Ohta K., et al. Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress. Free Radical Biology and Medicine. 2024. Vol. 212. P.199–206. doi: 10.1016/j.freeradbiomed.2023.12.014</mixed-citation><mixed-citation xml:lang="en">Chida T., Watanabe S., Ohta K., et al. Impact of amino acid substitutions in hepatitis C virus core region on the severe oxidative stress. Free Radical Biology and Medicine. 2024;212:199–206. doi: 10.1016/j.freeradbiomed.2023.12.014</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
